Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 472897, 10 pages
http://dx.doi.org/10.1155/2012/472897
Research Article

Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia

1Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan
2Department of Dentistry, Taipei Medical University Hospital, Taipei 110, Taiwan
3Department of Otolaryngology, Taipei Medical University Hospital, Taipei 110, Taiwan
4Department of Dermatology, Taipei Medical University Hospital, Taipei 110, Taiwan
5Department of Pharmacology, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan
6Department of Medical Technology, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

Received 18 June 2011; Accepted 5 November 2011

Academic Editor: Xiu-Min Li

Copyright © 2012 Chung-Hung Shih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Lee, J. Markowitz, J. O. Lee, and H. Lee, “Crystal structure of phosphodiesterase 4D and inhibitor complex,” FEBS Letters, vol. 530, no. 1–3, pp. 53–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. T. J. Torphy and L. B. Cieslinski, “Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle,” Molecular Pharmacology, vol. 37, no. 2, pp. 206–214, 1990. View at Google Scholar · View at Scopus
  3. Z. Kapui, P. Schaeffer, E. G. Mikus et al., “Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs,” Arzneimittel-Forschung, vol. 49, no. 8, pp. 685–693, 1999. View at Google Scholar · View at Scopus
  4. J. De Boer, A. J. Philpott, R. G. M. Van Amsterdam, M. Shahid, J. Zaagsma, and C. D. Nicholson, “Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors,” British Journal of Pharmacology, vol. 106, no. 4, pp. 1028–1034, 1992. View at Google Scholar · View at Scopus
  5. P. J. Silver, L. T. Hamel, M. H. Perrone, R. G. Bentley, C. R. Bushover, and D. B. Evans, “Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle,” European Journal of Pharmacology, vol. 150, no. 1-2, pp. 85–94, 1988. View at Google Scholar · View at Scopus
  6. E. Kim, H. O. Chun, S. H. Jung et al., “Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 14, pp. 2355–2358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Giembycz, “Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?” Drugs, vol. 59, no. 2, pp. 193–212, 2000. View at Google Scholar · View at Scopus
  8. K. Y. Yen, Pharmacology of Common Chinese Medicine (III), National Research Institute of Chinese Medicine, Taipei, Taiwan, 1971.
  9. P. Knekt, J. Kumpulainen, R. Järvinen et al., “Flavonoid intake and risk of chronic diseases,” American Journal of Clinical Nutrition, vol. 76, no. 3, pp. 560–568, 2002. View at Google Scholar · View at Scopus
  10. W. C. Ko, C. M. Shih, Y. H. Lai, J. H. Chen, and H. L. Huang, “Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships,” Biochemical Pharmacology, vol. 68, no. 10, pp. 2087–2094, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Gu, L. Zhou, Q. Du et al., “Hesperetin inhibits the maturation and function of monocyte-derived dendritic cells from patients with asthma,” Molecular Medicine Reports, vol. 2, no. 3, pp. 509–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Joseph Thompson and M. M. Appleman, “Multiple cyclic nucleotide phosphodiesterase activities from rat brain,” Biochemistry, vol. 10, no. 2, pp. 311–316, 1971. View at Google Scholar · View at Scopus
  13. H. H. Schneider, R. Schmiechen, M. Brezinski, and J. Seidler, “Stereospecific binding of the antidepressant rolipram to brain protein structures,” European Journal of Pharmacology, vol. 127, no. 1-2, pp. 105–115, 1986. View at Google Scholar · View at Scopus
  14. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Google Scholar · View at Scopus
  15. Y. Zhao, H. T. Zhang, and J. M. O'Donnell, “Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 2, pp. 565–572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Reeves, B. K. Leigh, and P. J. England, “The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors,” Biochemical Journal, vol. 241, no. 2, pp. 535–541, 1987. View at Google Scholar · View at Scopus
  17. A. Kanehiro, T. Ikemura, M. J. Mäkelä et al., “Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 173–184, 2001. View at Google Scholar · View at Scopus
  18. E. Hamelmann, J. Schwarze, K. Takeda et al., “Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 3, pp. 766–775, 1997. View at Google Scholar · View at Scopus
  19. G. E. Winterrowd and J. E. Chin, “Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation,” Journal of Immunological Methods, vol. 226, no. 1-2, pp. 105–118, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. B. N. Melgert, D. S. Postma, M. Geerlings et al., “Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice,” American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 6, pp. 880–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Robichaud, P. B. Stamatiou, S. L. C. Jin et al., “Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 1045–1052, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. W. W. Busse and R. F. Lemanske Jr., “Asthma,” New England Journal of Medicine, vol. 344, no. 5, pp. 350–362, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Revets, G. Pynaert, J. Grooten, and P. De Baetselier, “Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses,” Journal of Immunology, vol. 174, no. 2, pp. 1097–1103, 2005. View at Google Scholar · View at Scopus
  24. A. Vojdani and J. Erde, “Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I),” Evidence-Based Complementary and Alternative Medicine, vol. 3, no. 1, pp. 25–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Cher and T. R. Mosmann, “Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones,” Journal of Immunology, vol. 138, no. 11, pp. 3688–3694, 1987. View at Google Scholar · View at Scopus
  26. C. Taube, C. Duez, Z. H. Cui et al., “The role of IL-13 in established allergic airway disease,” Journal of Immunology, vol. 169, no. 11, pp. 6482–6489, 2002. View at Google Scholar · View at Scopus
  27. B. B. Vargaftig and M. Singer, “Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13,” American Journal of Respiratory Cell and Molecular Biology, vol. 28, no. 4, pp. 410–419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Tucker and C. H. Fanta, “Integrative inflammation pharmacology: asthma,” in Principles of Pharmacology the Pathophysiologic Basis of Drug Therapy, D. E. Golan, A. H. Tashjian Jr., E. J. Armstrong, J. M. Galanter, A. W. Armstrong, R. A. Arnaout et al., Eds., pp. 695–705, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2005. View at Google Scholar
  29. P. S. Foster, S. P. Hogan, A. J. Ramsay, K. I. Matthaei, and I. G. Young, “Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model,” Journal of Experimental Medicine, vol. 183, no. 1, pp. 195–201, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Clayton, G. Bardi, S. E. Bell et al., “A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation,” Journal of Experimental Medicine, vol. 196, no. 6, pp. 753–763, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Okkenhaug, A. Bilancio, G. Farjot et al., “Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice,” Science, vol. 297, no. 5583, pp. 1031–1034, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. K. S. Lee, H. K. Lee, J. S. Hayflick, Y. C. Lee, and K. D. Puri, “Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model,” FASEB Journal, vol. 20, no. 3, pp. 455–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. C. L. Emson, S. E. Bell, A. Jones, W. Wisden, and A. N. J. McKenzie, “Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13,” Journal of Experimental Medicine, vol. 188, no. 2, pp. 399–404, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Wei, X. Ci, X. Chu, M. Wei, S. Hua, and X. Deng, “Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model,” Inflammation. In press. View at Publisher · View at Google Scholar
  35. D. P. Westfall, W. T. Gerthoffer, and R. C. Webb, “Vasodilators and nitric oxide synthase,” in Human Pharmacology Molecular to Clinical, T. M. Brody, J. Larner, and K. P. Minneman, Eds., pp. 239–247, Mosby, St. Louis, Mo, USA, 1998. View at Google Scholar
  36. B. J. Lipworth, “Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease,” The Lancet, vol. 365, no. 9454, pp. 167–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Hatzelmann and C. Schudt, “Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 267–279, 2001. View at Google Scholar · View at Scopus
  38. L. M. Fabbri, P. M. Calverley, J. L. Izquierdo-Alonso et al., “Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials,” The Lancet, vol. 374, no. 9691, pp. 695–703, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. P. M. Calverley, K. F. Rabe, U. M. Goehring, S. Kristiansen, L. M. Fabbri, and F. J. Martinez, “Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials,” The Lancet, vol. 374, no. 9691, pp. 685–694, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Draheim, U. Egerland, and C. Rundfeldt, “Anti-Inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -glyoxylic acid amide (AWD 12–281), in human cell preparations,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 555–563, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Kuss, N. Hoefgen, S. Johanssen, T. Kronbach, and C. Rundfeldt, “In vivo efficacy in airway disease models of N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -glyoxylic acid amide (AWD 12–281), a selective phosphodiesterase 4 inhibitor for inhaled administration,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 1, pp. 373–385, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Hoppmann, W. Bäumer, C. Galetzka, N. Höfgen, M. Kietzmann, and C. Rundfeldt, “The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice,” Journal of Pharmacy and Pharmacology, vol. 57, no. 12, pp. 1609–1617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Giembycz, “Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?” British Journal of Pharmacology, vol. 155, no. 3, pp. 288–290, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Pagès, A. Gavaldà, and M. D. Lehner, “PDE4 inhibitors: a review of current developments (2005–2009),” Expert Opinion on Therapeutic Patents, vol. 19, no. 11, pp. 1501–1519, 2009. View at Google Scholar · View at Scopus
  45. G. Higgs, “Is PDE4 too difficult a drug target?” Current Opinion in Investigational Drugs, vol. 11, no. 5, pp. 495–498, 2010. View at Google Scholar · View at Scopus
  46. D. Singh, F. Petavy, A. J. Macdonald, A. L. Lazaar, and B. J. O'Connor, “The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma,” Respiratory Research, vol. 11, pp. 26–34, 2010. View at Google Scholar · View at Scopus
  47. A. B. Gottlieb, B. Strober, J. G. Krueger et al., “An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast,” Current Medical Research and Opinion, vol. 24, no. 5, pp. 1529–1538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. A. B. Burgin, O. T. Magnusson, J. Singh et al., “Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety,” Nature Biotechnology, vol. 28, no. 1, pp. 63–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. S. L. Jin, W. Richter, and M. Conti, “Insights into the physiological functions of PDE4 from knockout mice,” in Cyclic Nucleotide Phosphodiesterases in Health and Disease, J. A. Beavo, S. H. Francis, and M. D. Houslay, Eds., pp. 323–346, CRC Press, Boca Raton, Fla, USA, 2007. View at Google Scholar
  50. K. Fan Chung, “Phosphodiesterase inhibitors in airways disease,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 110–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Robichaud, C. Savoie, P. B. Stamatiou, F. D. Tattersall, and C. C. Chan, “PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway,” Neuropharmacology, vol. 40, no. 2, pp. 262–269, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Robichaud, C. Savoie, P. B. Stamatiou et al., “Assessing the emetic potential of PDE4 inhibitors in rats,” British Journal of Pharmacology, vol. 135, no. 1, pp. 113–118, 2002. View at Google Scholar · View at Scopus